Terrence Flynn

Terrence Flynn from Morgan Stanley asked about new insights gained from the differential outcomes in the two prior Phase III trials for itepekimab in COPD and potential changes or optimizations for a contemplated third Phase III trial to improve success likelihood.

Answer

Regeneron President and CSO, George Yancopoulos, declined to comment on specific competitive issues or insights due to an upcoming meeting with the FDA, which will inform their future strategy for itepekimab in COPD.

Terrence Flynn inquired about Regeneron's IL-33 antibody, itepekimab, in COPD, seeking insights from the differential outcomes in prior Phase III trials and potential optimization strategies for a planned third trial.

Answer

President and CSO George Yancopoulos declined to comment on specific insights or optimization strategies due to competitive issues and pending discussions with the FDA regarding the strategy for a potential third Phase III trial.